DEXMEDETOMIDINA COMO COADYUVANTE EN SEDACION PARA GINECOLOGIA
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rev Cient Cienc Méd
Abstract
Introducción: Actualmente no se cuenta con experiencia sobre el uso de dexmedetomidina intranasal para procedimientos ginecológicos en el medio. Objetivos: Demostrar los efectos del uso intranasal de dexmedetomidina en sedación para procedimientos gineco-obstétricos. Métodos: Es un ensayo clínico no controlado, prospectivo a simple ciego; tomando 24 pacientes de un universo de 80 pacientes, se administró 0,9 pg/kg de dexmedetomidina intranasal antes de realizar el procedimiento; se procesó en IBM-SPPS v.25 ®. Cálculo de media y DE en cuantitativas y valor p < 0,05 significativo. Resultados: Edad media de 32 años; frecuencia cardiaca basal 70 lat/min, siendo significativo posterior a la inducción y al concluir el procedimiento; la presión arterial media se mantuvo entre 82 a 73 mmHg, no significativo; la Escala Visual Numérica se encontró de 0 en 18 pacientes; durante la inducción y mantenimiento con Infusión Controlada se encontró entre 2 ng/ml de remifentanil y 2 mcg/ml de propofol; 18 pacientes no presentaron complicaciones. Conclusiones: Provee estabilidad hemodinámica a la dosis usada, sin efectos adversos tras administración de dexmedetomidina y produce una reducción de las dosis de los medicamentos de inducción y mantenimiento.
Introduction: We do not have experience on the use of intranasal dexmedetomidine for gynecological procedures in the environment. Objectives: To demonstrate the effects of intranasal use of dexmedetomidine in sedation for obstetric gynecological procedures. Methods: a prospective, longitudinal, single-blind, uncontrolled clinical trial was conducted; Taking 24 patients from a universe of 80 patients, 0.9 pg/kg of intranasal dexmedetomidine was administered prior to performing the procedure. it was processed in IBM-SPPS v.25 ®. Calculation of mean and SD in quantitative and p value < 0.05 significant. Results: average age of 32 years old; basal heart rate 70 beats / min, being significant after induction and at the end of the procedure; the mean arterial pressure remained between 82 to 73 mmHg, not significant;Visual Numeric Scale was found from 0 in 18 patients; during induction and maintenance with Target Control Infusion it was found between 2 ng / ml of remifentanil and 2 mcg / ml of propofol. There were no complications in 18 patients. Conclusions: it provides hemodynamic stability at the dose used without adverse effects after administration of dexmedetomidine and produces a reduction in the doses of induction and maintenance drugs.
Introduction: We do not have experience on the use of intranasal dexmedetomidine for gynecological procedures in the environment. Objectives: To demonstrate the effects of intranasal use of dexmedetomidine in sedation for obstetric gynecological procedures. Methods: a prospective, longitudinal, single-blind, uncontrolled clinical trial was conducted; Taking 24 patients from a universe of 80 patients, 0.9 pg/kg of intranasal dexmedetomidine was administered prior to performing the procedure. it was processed in IBM-SPPS v.25 ®. Calculation of mean and SD in quantitative and p value < 0.05 significant. Results: average age of 32 years old; basal heart rate 70 beats / min, being significant after induction and at the end of the procedure; the mean arterial pressure remained between 82 to 73 mmHg, not significant;Visual Numeric Scale was found from 0 in 18 patients; during induction and maintenance with Target Control Infusion it was found between 2 ng / ml of remifentanil and 2 mcg / ml of propofol. There were no complications in 18 patients. Conclusions: it provides hemodynamic stability at the dose used without adverse effects after administration of dexmedetomidine and produces a reduction in the doses of induction and maintenance drugs.
Description
Vol. 24, No. 2